Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer

BMC Cancer

Research Article

Hiroki Ito¹  Yumiko Yokomizo¹  Kazuhide Makiyama¹  Yusuke Ito¹  Masahiro Yao¹  Takashi Kawahara²  Hiroshi Miyamoto³  Yasuhide Miyoshi⁴  Jun-ichi Teranishi⁴  Hiroji Uemura⁴  Hitoshi Ishiguro⁵ 

[1] Department of Urology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan;Department of Urology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan;Departments of Urology and Renal Transplantation, Yokohama City Medical Center, Yokohama, Japan;Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, USA;Departments of Urology and Renal Transplantation, Yokohama City Medical Center, Yokohama, Japan;Photocatalyst Group, Special Research Laboratory, Kanagawa Academy of Science and Technology, Kawasaki, Japan;

关键词: Prostate cancer;    Biomarker;    Neutrophil-to-lymphocyte ratio;    Metastasis;   

DOI  :  10.1186/s12885-016-2134-3

 received in 2015-10-18, accepted in 2016-02-07,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundThe neutrophil-to-lymphocyte ratio (NLR), a simple marker of the systemic inflammatory response in critical care patients, has been suggested as an independent prognostic factor for several solid malignancies. We investigated the utility of pretreatment NLR as a prognosticator in patients who presented with metastatic prostate cancer.MethodsWe first investigated the correlation between NLR and prostate-specific antigen (PSA) levels in 1464 men who had both tests and were found to have prostate cancer on their biopsies at our institution from 1999 to 2015. We then assessed the relationship between pretreatment NLR and the prognosis in 48 patients who were diagnosed with prostate cancer metastasized to the lymph node and/or bone.ResultsThe NLR value was significantly elevated in men with higher PSA than in those with lower PSA (p < 0.001). In patients with metastatic prostate cancer, NLR (cut-off point of 3.37 determined by the AUROC curve) was correlated with both cancer-specific (p = 0.018) and overall (p = 0.008) survivals.ConclusionsPretreatment NLR may function as a new biomarker that precisely predicts the prognosis in patients with metastatic prostate cancer.

【 授权许可】

CC BY   
© Kawahara et al. 2016